Novartis AG
TREATMENT OF CANCER USING GFR ALPHA-4 CHIMERIC ANTIGEN RECEPTOR
Last updated:
Abstract:
The present invention relates to compositions and methods for treating diseases, disorders or conditions associated with the expression of the Glycosyl-phosphatidylinositol (GPI)-linked GDNF family .alpha.-receptor 4 (GFR.alpha.4).
Status:
Application
Type:
Utility
Filling date:
23 Oct 2020
Issue date:
18 Mar 2021